Breaking Finance News

Zacks Investment Research disclosed Hill-Rom Holdings, Inc. (NYSE:HRC), stepping up its target to $90.00 earlier today

Yesterday Hill-Rom Holdings, Inc. (NYSE:HRC) traded -1.81% lower at $80.55. The company’s 50-day moving average is $75.30 and its 200-day moving average is $75.12. The last closing price is up 0.64% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 1,612,576 shares of the stock traded hands, up from an average trading volume of 490,698

Zacks Investment Research raised the target price of Hill-Rom Holdings, Inc. (NYSE:HRC) to $90.00 reporting a possible upside of 0.12%.

See Chart Below

Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. has a 52 week low of $50.50 and a 52 week high of $84.65 with a P/E ratio of 44.06 The company’s market cap is currently $0.

General Information About Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company's products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *